MedTrace Logo

Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala

NCT03696303 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 959

Last updated 2022-05-04

No results posted yet for this study

Summary

This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of age or younger in Guatemala.

Conditions

  • Community-acquired Pneumonia
  • Streptococcus Pneumoniae Infection

Interventions

OTHER

Urinary antigen detection assay

Screening for Ag level in S. pneumoniae urinary antigen detection assay.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Edwin Asturias, MD · University of Colorado, Denver

Eligibility

Min Age
31 Days
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Guatemala

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696303 on ClinicalTrials.gov